

Provisional Translation
from Japanese Original

May 17, 1982
Notification PB No.463
Final revision May 15, 1998

The Standards for Marketing Approval of Laxatives

1. Scope of Laxatives

The scope of preparations subject to these standards covers oral medicines intended for the relief of the symptoms of constipation or the elimination of intestinal contents (except for preparations covered by the Standards for Marketing Approval of gastrointestinal medicines and Kampo medicine* formulas.

* Kampo medicine is traditional Japanese medicine.

2. Approval Standards

The approval standards for laxatives are as follows.

For preparations not conforming to these standards, concerning the efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- (a) The types of active ingredients that may be used in laxatives are shown in Tables 1 and 2.
- (b) At least 1 of the active ingredients in Table 1 must be used.
- (c) Preparations mainly containing the active ingredients from Group I, II, III, or IV in Column A of Table 1 may be made by mutual combination of the active ingredients in these 4 groups, and may also include the active ingredients in Table 2.
- (d) When active ingredients from Group I, Group II, or Group III in Column A of Table 1 are combined, only 1 ingredient from each group should be used. When active ingredients from Group IV are used, up to 4 active ingredients from this group may be included.
However, when active ingredients from 2 or more groups, among Groups I, II, III, and IV, are combined, up to 4 active ingredients from Column A of Table 1 (except Group V) may be combined.
- (e) The following combinations are not permitted among the active ingredients of Group IV in Column A of Table 1: Aloes with aloin, Cascara sagrada bark with casanthranol, Pharbitis seeds with Pharbitis seed resin, Senna or Senna fruit with sennoside or sennosides A and B, and Jalap tuber with Jalap resin.
- (f) For preparations mainly containing the active ingredients from Group V of Column A in Table 1, combinations with the other active ingredients in these standards are not permitted.
- (g) When the active ingredients from Column B of Table 1 are used as a main ingredient, only 1 active ingredient can be used in a preparation and none of the other active ingredients covered by these standards should be combined.
- (h) When the active ingredients from Column I or II of Table 2 are combined, up to 4 active ingredients in the same column may be used.

When active ingredients in both Columns I and II of Table 2 are combined, up

to 5 of the active ingredients from the whole table may be used.

- (i) Other than the active ingredients in Tables 1 and 2, vitamins in the Appendix may be included if there is a sound basis for their combination and the effect is mild.

(2) Quantities of Active Ingredients

- (a) The maximum single and daily doses of the active ingredients from Column A of Table 1 are as indicated in the table.
- (b) The maximum single doses of the active ingredients from Column B of Table 1 are as indicated in the table.
- (c) The maximum daily dose of each of the active ingredients from Column I (except live bacteria for intestinal regulation) and Column II of Table 2 are as given in the table. The maximum single dose should be 1/3rd of the maximum daily dose.
- (d) When 2 or more of the active ingredients from Column A of Table 1 are combined, the sum of the values obtained by dividing the amounts of each of the active ingredients by their respective maximum daily doses should not exceed 2.
- (e) When 2 or more of the active ingredients from either Column I or Column II of Table 2 are combined, the sum of the values obtained by dividing the amounts of each of the active ingredients by their respective maximum daily doses should not exceed 2 in each column.
- (f) The minimum daily dose of live bacteria for intestinal regulation from Column I of Table 2 is as given in the same group, and the minimum single dose should be 1/3rd of the minimum daily dose.

(3) Dosage Forms

The dosage forms are capsules, granules, pills, fine granules, powders, lingual tablets (limited to preparations mainly containing the active ingredients from Group V of Column A of Table 1), tablets, infusions, decoctions, chocolate preparations and liquids for oral use (limited to syrups and preparations mainly containing the active ingredients from Group I of Column A or those from Column B of Table 1).

(4) Dosage and Administration

- (a) Preparations should, in principle, be taken by oral administration 1 to 3 times daily, and the administration times and intervals must be clearly indicated. When the preparation is taken twice a day or more, the interval between doses must be not less than 4 hours. However, preparations mainly containing the active ingredients from Column B of Table 1 should be taken not more than once a day, to be taken when required.
- (b) For preparations mainly containing the active ingredients from Column A of Table 1, the dosage range for different degrees of constipation must be indicated. Since there are individual differences with respect to the degree of constipation, it must be stated that the minimum dose should be taken initially and then the dose should be gradually increased (or decreased) depending on the condition of relief.
- (c) In principle, dosage for children under 3 years of age is not permitted.
- (d) Regardless of the rules described in (a), (b), or (c), preparations mainly containing the active ingredients from Group V of Column A in Table 1 will be approved only for small children and infants. Entries for dosage and

administration should be made in accordance with Table 5.

- (e) In the case of infusions and decoctions, the method of preparation at the time of use should be clearly indicated.
- (f) For capsules, and pills and tablets larger than 6 mm in diameter, dosage for children under 5 years of age is not approved.
- (g) The maximum single and daily doses for those under 15 years of age are the values obtained by multiplying the coefficients corresponding to the respective age groups in Table 3 by the maximum single and daily doses shown in Tables 1 and 2.

However, the minimum daily dose of live bacteria for intestinal regulation from Column I of Table 2 should be applied irrespective of age.

(5) Indications

- (a) The indications for preparations mainly containing the active ingredients from Column A of Table 1 are shown from Column I of Table 4. However, the indications for preparations mainly containing the active ingredients from Group V of Column A in Table 1 are as specified in Table 5.
- (b) The indications for preparations mainly containing the active ingredients from Column B of Table 1 are as specified from Column II of Table 4.

(6) Packaging Units

The maximum volume of syrup containers is a 2-day supply at the maximum daily dose for adults (15 years of age and over).

Table 1

| Classification | | Active ingredients | Maximum single dose (g) | | Maximum daily dose (g) | |
|-----------------------------------|---------------------|---|--|------------|--|--|
| Column A | Group I | Magnesium oxide | 0.7 (2) | | 2 | |
| | | Magnesium hydroxide | 0.7 (2.1) | | 2.1 | |
| | | Magnesium carbonate | 2.7 | | 8 | |
| | | Sodium sulfate | 5 | | 15 | |
| | | Magnesium sulfate | 5 | | 15 | |
| | Group II | Carboxymethylcellulose calcium | 2 | | 6 | |
| | | Carboxymethylcellulose sodium | 2 | | 6 | |
| | | Plantago ovata coating (Ispaghula husk) | 3.5 | | 10.5 | |
| | Group III | Sodium dioctyl-sulfosuccinate | 0.067 (0.12) | | 0.2 | |
| | Group IV | Aloin | 0.02 | | 0.06 | |
| Sulfur | | 0.5 | | 1.5 | | |
| Casanthranol | | 0.067 (0.1) | | 0.2 | | |
| Sennoside (as sennosides A and B) | | 0.016 (0.024) | | 0.048 | | |
| Sennosides A and B | | 0.016 (0.024) | | 0.048 | | |
| Bisacodyl | | 0.007 (0.015) | | 0.02 | | |
| | | Powder (g) | Extract (g) (converted to crude drug amount) | Powder (g) | Extract (g) (converted to crude drug amount) | |
| Aloes | | 0.25 (0.38) | 0.25 (0.38) | 0.75 | 0.75 | |
| Rose fruit | | 0.67 | 1.7 | 2 | 5 | |
| Cascara sagrada bark | | — | 1 (1.5) | — | 3 | |
| Pharbitis seed | | 0.1 | — | 0.3 | — | |
| Pharbitis seed resin | | 0.05 | — | 0.15 | — | |
| Senna | | 0.5 (0.75) | 2 (3) | 1.5 | 6 | |
| Senna fruit | | 0.5 (0.75) | — | 1.5 | — | |
| Rhubarb | | 1 (1.5) | 1.4 (2) | 3 | 4 | |
| Frangula bark | — | 1 (1.5) | — | 3 | | |
| Jalap root | 0.1 | — | 0.3 | — | | |
| Jalap resin | 0.05 | — | 0.15 | — | | |
| Group V | Malt extract | As per Table 5 | | | | |
| Column B | Aromatic castor oil | 20 mL | | — | | |
| | Castor oil | 20 mL | | — | | |

(Note) Figures in parentheses are the maximum single dose applicable when the dosage is once or twice a day.

Table 2

| Classification | Active ingredient | Maximum daily dose (g) | |
|----------------|---|------------------------|--|
| | | Powder (g) | Extract (g) (converted to crude drug amount) |
| Column I | Ursodeoxycholic acid | | 0.06 |
| | Oxycolanate | | 0.15 |
| | Dried yeast | | 10 |
| | Cholic acid | | 0.9 |
| | Dimethylpolysiloxane | | 0.18 |
| | Live bacteria for intestinal regulation | | 1×10 ⁶ (*) |
| | Sodium bicarbonate | | 3 |
| | Dehydrocholic acid | | 0.5 |
| | Linseed | 2 | - |
| | Japanese valerian | 2 | - |
| | Glycyrrhiza | 1.5 | 5 |
| | Cassia seed | 3 | 10 |
| | Smilax rhizome | 1.5 | 5 |
| | Gardenia fruit | 1 | 3 |
| | Rehmannia root | 1.5 | 5 |
| | Peony root | 2 | 5 |
| | Houttuynia herb | 5 | 15 |
| | Cimicifuga rhizome | 1 | 3 |
| | Cnidium rhizome | 1.5 | 5 |
| | Jujube | 1.5 | 5 |
| | Bile extract (powder) | 0.5 | - |
| | Japanese angelica root | 1.5 | 5 |
| | Animal bile | 0.5 | - |
| | Moutan bark | 1.3 | 4 |
| | Hemp fruit | 5 | - |
| | Coix seed | 6 | 20 |

(*) Minimum daily dose

| Classification | Active ingredient | Maximum daily dose (g) | |
|----------------|---------------------------|------------------------|--|
| | | Powder (g) | Extract (g) (converted to crude drug amount) |
| Column II | Fennel | 0.5 | 1.5 |
| | Plectranthus herb | 1.5 | 5 |
| | Scutellaria root | 1.5 | 3 |
| | Phellodendron Bark | 1.5 | 1.5 |
| | Coptis Rhizome | 0.75 | 1.5 |
| | Zeodary | 1.5 | 1.5 |
| | Calamus Root | 1 | 3 |
| | Immature orange | 1 | 2.5 |
| | Cinnamon Bark | 0.5 | 2.5 |
| | Gentian | 0.25 | 0.75 |
| | Magnolia bark | 0.75 | 2.5 |
| | Condurango | 1.5 | 4.5 |
| | Resurrection Lily Rhizome | 1 | 3 |
| | Ginger | 0.5 | 1.5 |
| | Swertia herb | 0.025 | 0.75 |
| | Atractylodes | 1 | 2.5 |
| | Lancea Rhizome | | |
| | Perilla Herb | 0.5 | 1 |
| | Citrus Unshiu Peel | 1.5 | 2.5 |
| | Bitter orange peel | 1.5 | 2.5 |
| | Ginseng | 1.5 | 3 |
| | Mentha herb | 0.5 | 1.5 |
| | Mentha oil | | 0.015 |
| | Atractylodes rhizome | 1 | 2.5 |
| | Nux vomica extract | | 0.015 |
| | d-Menthol | | 0.09 |
| | l-Menthol | | 0.09 |
| | Saussurea root | 0.5 | 1.5 |
| | Japanese gentian | 0.25 | 0.75 |

Table 3 Age coefficient

| Age | Coefficient |
|-----------------------------|-------------|
| 15 years of age and over | 1 |
| 11 to under 15 years of age | 2/3 |
| 7 to under 11 years of age | 1/2 |
| 3 to under 7 years of age | 1/3 |

Table 4

| | Indications |
|-----------|--|
| Column I | <ul style="list-style-type: none"> ○ Constipation ○ Relief of the following symptoms due to constipation: dull headache, hot flush, skin roughness, eruption, loss of appetite (anorexia), fullness in the abdomen, abnormal fermentation in the intestines, and hemorrhoids |
| Column II | ○ Rapid excretion of intestinal contents (food poisoning, etc.) |

Table 5

| Dosage and administration (maximum single dose) | Indications |
|--|--|
| 1 to under 3 years of age: 15 g/dose 6 months to under 1 year of age: 9 g/dose Under 6 months of age: 9 g/dose Take orally up to 3 times a day in each case | Constipation in infants and small children |

Appendix

| Ingredients | Maximum daily dose |
|---|--------------------|
| Vitamin B ₁ , its derivatives, and their salts | 25 mg |
| Vitamin B ₆ | 50 mg |
| Nicotinamide | 5 mg |
| Calcium panthothenate | 30 mg |

(Note) Nicotinamide is to be combined only when lactic acid bacteria or lactic acid producing bacteria are used as live bacteria for intestinal regulation.

Provisional Translation
from Japanese Original

Jun 1, 1984
Notification PB No.381

The Standards for Marketing Approval of Antivertigo Medicines

1. Scope of Antivertigo Medicines

The scope of preparations subject to these standards covers oral medicines (Kampo medicine* formulas are not covered) intended to prevent or relieve symptoms associated with motion sickness, such as dizziness, nausea, and headaches.

*Kampo medicine is traditional Japanese medicine.

2. Approval Standards

The approval standards for antivertigo medicines intended to prevent or relieve symptoms associated with motion sickness (hereinafter referred to as motion sickness drugs) are as follows.

For motion sickness drugs and antivertigo medicines other than motion sickness drugs not conforming to these standards, efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- (a) The types of active ingredients that may be combined are shown in Table 1.
- (b) At least one ingredient from either Column I or Group 1 of Column II of Table 1 must be combined.
- (c) Though the active ingredients in Column I, II, III, IV, V, VI, or VII of Table 1 may all be mutually combined, the types of active ingredients that may be combined in oral liquid preparations should be those in Column I, Group 1 of Column II, Column V, and Column VII.
- (d) Up to 2 ingredients from each of Column I or V in Table 1 may be included (however, only 1 ingredient from each of Group 1 or 2 of Column V may be combined).
One active ingredient each from Column II, III, IV, VI, or VII may be included.
- (e) Other than the active ingredients in Table 1, vitamins listed in the Appendix may be included if there is a sound basis for their combination and the effect is mild.

(2) Quantities of Active Ingredients

- (a) Table 1 shows the maximum single and daily doses for each of the active ingredients listed.
- (b) When 1 active ingredient listed in either Column I or Group 1 of Column II of Table 1 is used, the lower limit of the single dose of each active ingredient should be half of the maximum single dose.
- (c) When 2 of the active ingredients in Column I of Table 1 are used, the lower limit of the single dose of each active ingredient should be 1/5th of the maximum single dose. In addition, the sum of the values obtained by dividing the amounts of each active ingredient by their respective maximum single dose should be not less than 0.5 and not more than 1.

- (d) When active ingredients in Column I or Group 1 of Column II of Table are combined mutually, the lower limit of the single dose of each active ingredient should be 1/5th of the maximum single dose. Further, the sum of the values obtained by dividing the amounts of each active ingredient by their respective maximum single dose should be not less than 0.5 and not more than 2.
- (e) The lower limit of the single dose of each active ingredient in Group 2 or 3 of Column II, Column III, Column IV, Column V, or Column VI of Table 1 should be 1/5th of the maximum single dose.
- (f) When 2 ingredients from Column V of Table 1 are combined, the sum of the values obtained by dividing the amounts of each active ingredient by their respective maximum single dose should not exceed 1.
- (g) The lower limit of the single dose of each active ingredient in Column VII of Table 1 should be 1/10th of the maximum single dose.
- (h) The maximum daily dose of each active ingredient listed in the Appendix is as specified in the table.

(3) Dosage Form

The dosage forms are capsules, granules, pills, fine granules, powders, tablets (including chewable tablets), and oral liquids.

(4) Dosage and Administration

- (a) Dosage is by oral administration from 1 to 3 times a day (with the exception of 1 to 4 times a day for single active ingredient preparations containing dimenhydrinate). The time of administration and intervals between doses should be clearly indicated. For medicines designed to be taken twice a day or more, the interval between doses must be at least 4 hours.
- (b) In principle, dosage for children under 3 years of age is not approved. In the case of preparations containing ethyl aminobenzoate, dosage is not approved for children under 6 years of age; and as for preparations containing promethazine hydrochloride or promethazine methylene disalicylate, dosage for those under 15 years of age is not approved.
- (c) For capsules, and pills and tablets larger than 6 mm in diameter, dosage for children under 5 years of age is not approved.
- (d) The maximum single and daily doses for children under 15 years of age is obtained by multiplying the maximum single and daily doses given in Table 1 by the coefficient for each age group given in Table 2.
- (e) The method of administration must be clearly indicated for chewable tablets.

(5) Indications

The indications are "prevention and relief of dizziness, nausea, and headache associated with motion sickness."

(6) Packaging Units

In principle, the volume of containers for oral liquids should be the amount for a single dose and should not exceed 30 mL.

Table 1

| Column | Active ingredient | Maximum single dose (mg) | Maximum daily dose (mg) | |
|--------------|---|---|-------------------------|------|
| Column I | Difenidol hydrochloride | 25 | 75 | |
| | Diphenylpyraline hydrochloride | 4 | 12 | |
| | Diphenhydramine hydrochloride | 50 | 150 | |
| | Promethazine hydrochloride | 25 | 50 | |
| | Meclizine hydrochloride | 50 | 75 | |
| | Diphenhydramine salicylate | 60 | 180 | |
| | Dimenhydrinate | 50 | 200 | |
| | Diphenhydramine tannate | 150 | 450 | |
| | Fenethazine tannate | 30 | 90 | |
| | Diphenylpyraline teoate | 3 | 9 | |
| | Diphenhydramine fumarate | 60 | 180 | |
| | Promethazine methylenedisalicylate | 30 | 60 | |
| | <i>d,l</i> -Chlorpheniramine maleate | 4 | 12 | |
| | <i>d</i> -Chlorpheniramine maleate | 2 | 6 | |
| | Pheniramine maleate | 30 | 90 | |
| Column II | Group I | Scopolamine hydrobromide | 0.25 | 0.50 |
| | Group II | Oxyphencyclimine hydrochloride | 2.34 | 7 |
| | | Dicyclomine hydrochloride | 10 | 30 |
| | | Methixene hydrochloride | 2.92 | 8.75 |
| | | Atropine methylbromide | 2 | 6 |
| | | Anisotropine methylbromide | 10 | 30 |
| | | Scopolamine methylbromide | 1.6 | 4.8 |
| | | Hyoscyamine methylbromide | 0.75 | 2.25 |
| | | Metylbenactyzium bromide | 10 | 30 |
| | | Belladonna extract | 20 | 60 |
| | | Isopropamide iodide | 2.5 | 7.5 |
| | | Diphenylpiperidinomethyldioxolan iodide | 20 | 60 |
| | Scopolia extract | 20 | 60 | |
| Group III | Papaverine hydrochloride | 30 | 90 | |
| Column III | Ethyl aminobenzoate | 100 | 300 | |
| | Cerium oxalate | 100 | 300 | |
| | Ethyl <i>p</i> -piperidinoacetylaminobenzoate | 200 | 600 | |
| Column IV | Allylisopropylacetylurea | 60 | 180 | |
| | Bromovalerylurea | 200 | 600 | |
| Column V | Group I | Caffeine | 50 | 150 |
| | | Caffeine citrate | 100 | 300 |
| | | Anhydrous caffeine | 50 | 150 |
| | Group II | Aminophylline | 100 | 300 |
| | | Diprophylline | 100 | 300 |
| Theophylline | 100 | 300 | | |
| Column VI | Sodium bicarbonate | 1,000 | 3,000 | |
| Column VII | Mentha oil | 5 | 15 | |
| | <i>d,l</i> -Menthol | 30 | 90 | |
| | <i>l</i> -Menthol | 30 | 90 | |

Table 2

| Age | Coefficient |
|-----------------------|-------------|
| 15 years old and over | 1 |
| 11 years old-Under 15 | 2/3 |
| 7 years old-Under 11 | 1/2 |
| 3 years old-Under 7 | 1/3 |

Appendix

| Ingredients | Maximum daily dose (mg) |
|---|-------------------------|
| Vitamin B ₁ , its derivatives, and their salts | 25 |
| Vitamin B ₂ , its derivatives, and their salts | 12 |
| Vitamin B ₆ , its derivatives, and their salts | 50 |
| Nicotinamide | 60 |
| Calcium panthothenate | 30 |

Provisional Translation
from Japanese OriginalJul 29, 1986
Notification PB No.623

The Standards for Marketing Approval of Ophthalmic Medicines

1. Scope of Ophthalmic Medicines

The scope of preparations subject to these standards covers medicines to be applied to the mucous membrane of the eyes to treat symptoms of eye diseases and those to be used when inserting contact lenses.

2. Approval Standards

The approval standards for ophthalmic medicines are as follows.

For preparations not conforming to these standards, efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- (a) Active ingredients that may be used in ophthalmic medicines are listed in Table I.
- (b) At least 1 active ingredient from Column A, B, C, or D; Group 1, 2, or 3 of Column E; Column F, G, or H; Group 1 of Column I; or Column J in Table I must be used.
- (c) Preparations mainly containing the active ingredients in Column A, B, C, or D; Group 1, 2, or 3 of Column E; or Group 1 of Column F (hereinafter referred to as "ordinary eye drops") in Table I may be formulated through the mutual combination of any of the active ingredients in these columns and groups, and may also include the active ingredients in Group 4, 5, or 6 of Column E or those in Group 2 or 3 of Column F in Table I.
- (d) Preparations mainly containing active ingredients in Column G (hereinafter referred to as "antibacterial eye drops") in Table I may include up to 3 active ingredients from Column A, B, C, D, E, or F.
- (e) Preparations mainly containing active ingredients in Groups 2 or 3 of Column F or those in Column H of Table I (hereinafter referred to as "artificial tears") may be formulated through the mutual combination of any of the active ingredients in Group 2 or 3 of Column F or those in Column H, and may also include the active ingredients in Group 1 of Column F or those in Column I.
- (f) Preparations mainly containing active ingredients in Group 1 of Column I (hereinafter referred to as "contact lens insertion preparations") of Table I may also include active ingredients in Column F or H or those in Group 2 of Column I.
- (g) Preparations mainly containing active ingredients in Column C, D, H, or J, listed in Table I, are used for washing the eyes and are referred to as "eyewashes." Those mainly containing active ingredients from Column C or D may be formulated by combining any of the active ingredients from Column C or D, and may also include active ingredients from Column E or F. Preparations mainly containing active ingredients from Column H or J of

Table I can include only 1 active ingredient from Column H or J, and no other active ingredients mentioned in these standards should be used.

- (h) When the active ingredients from Column A, D, or G of Table I are combined, only 1 ingredient from each column may be used.
 - (i) When the active ingredients from Column C, E, or F of Table I are combined, up to 3 ingredients from each column may be used, but only 1 from each group is permitted.
- (2) Quantities of Active Ingredients
- (a) The maximum concentrations of the active ingredients from Column A, B, C, D, E, F, or G; Group 1 of Column I; or Column J should be those given in mentioned in Table I.
However, in the case of eyewashes, the maximum concentrations of the active ingredients in Columns C, D, E, and F should be 1/10th of the maximum concentrations mentioned in Table I.
 - (b) When 2 or more of the active ingredients from any 1 of Column C, E, or F of Table I are combined, the sum of the values obtained by dividing the concentration of each active ingredient by its respective maximum concentration should not exceed 2.
However, in the case of eyewashes, the maximum concentration stipulated in (2) (a) shall apply.
 - (c) In the case of ordinary eye drops, when only 1 active ingredient from Column A, B, C, or D; Group 1, 2, or 3 of Column E; or Group 1 of Column F of Table I is included, the minimum concentration of the ingredients should be half of the maximum concentration. When 2 or more of these active ingredients are combined, the minimum concentration of each shall be 1/5 of the maximum concentration.
 - (d) In the case of antibacterial eye drops, when active ingredients in Column G of Table I are included, the minimum concentration of these active ingredients should be half of the maximum concentration. When active ingredients from Column A, B, C, or D; Group 1, 2, or 3 of Column E; or Group 1 of Column F are included, their minimum concentrations should be 1/5 of the maximum concentration.
 - (e) In the case of artificial tears, when active ingredients listed in Column F or Group 1 of Column I in Table I are used, their minimum concentrations should be 1/10th the maximum concentration. pH values must be in the range of 5.5 to 8.0, and specific osmotic pressures (specific osmotic pressures with respect to physiological saline) must be in the range of 0.85 to 1.55 when pH and osmotic pressures are measured by the methods specified elsewhere.
 - (f) For contact lens insertion preparations, when 1 active ingredient from Group 1 of Column I in Table I is used, the minimum concentration should be half of the maximum concentration. When 2 active ingredients are included, their minimum concentrations should be 1/5th of the maximum concentration. When active ingredients in Column F are combined, their minimum concentrations should be 1/10th of the maximum concentration.
 - (g) In the case of eyewashes, when active ingredients from Column C, D, or J of Table I are combined, the minimum concentration should be 1/5th of the maximum concentration specified in (2) (a). When active ingredients in Column E or F are used, the minimum concentration should be 1/10th of the maximum concentration specified in (2) (a). pH values must be in the range of 5.5 to 8.0, and specific osmotic pressures (specific osmotic pressure with respect to physiological saline) must be in the range of 0.60 to 1.55 when pH and osmotic pressures are measured by the methods specified elsewhere.

- (h) Unless otherwise specified, when active ingredients in Groups 4, 5, and 6 of Column E, or Groups 2 and 3 of Column F in Table I are combined, the minimum concentration should be 1/10th of the maximum concentration.

(3) Dosage Form

The dosage form shall be ophthalmic solutions (eye drops and eyewashes).

(4) Dosage and Administration

- (a) Ordinary eye drops, antibacterial eye drops, and artificial tears are to be administered 3 to 6 times a day.
- (b) For contact lens insertion preparations, the detailed method of use should be stated.
- (c) Eyewashes are to be used 3 to 6 times a day to wash the eyes.

(5) Indications

- (a) The range of indications for ordinary eye drops is shown in Table II-1. However, for indications in the upper column of the following table to be claimed, at least 1 of the ingredients from the columns listed in the corresponding lower column must be included.

| Upper column | Lower column |
|--|---|
| Conjunctival congestion | Columns A, C, and D |
| Inflammation of eyes (snow blindness), blepharitis (inflammation of the eyelids), and itchy eyes due to ultraviolet light and other rays | Columns C and D and Group 1 of Column E |

- (b) The range of indications for antibacterial eye drops is shown in Table II-2.
- (c) The range of indications for artificial tears is shown in Table II-3. However, "treatment of feeling of discomfort when inserting soft contact lenses" cannot be claimed when the effect is brought about due to the effect of ingredients on the lenses, such as adsorption on the lenses.
- (d) The range of indications for contact lens insertion preparations is shown in Table II-4. However, "ease of insertion of soft contact lenses" cannot be claimed when the effect is brought about due to the effect of ingredients on the lenses, such as adsorption on the lenses.
- (e) The range of indications for eyewashes is shown in Table II-5.
- (6) Packaging Units
- (a) The maximum volume of containers for ordinary eye drops, antibacterial eye drops, and artificial tears is 20 mL.
- (b) The maximum volume of containers for contact lens insertion preparations is 100 mL.
- (c) The maximum volume of containers for eyewashes is 500 mL.

Table I

| Column | Group | Active ingredient | Maximum concentration (%) |
|---------------------|---|--|---------------------------|
| A | | Epinephrine | 0.003 |
| | | Epinephrine hydrochloride | 0.003 (as epinephrine) |
| | | Ephedrine hydrochloride | 0.1 |
| | | Terahydrozoline hydrochloride | 0.05 |
| | | Naphazoline hydrochloride | 0.003 |
| | | Naphazoline nitrate | 0.003 |
| | | Phenylephrine hydrochloride | 0.1 |
| | <i>d</i> -Methylephedrine hydrochloride | 0.1 | |
| B | | Neostigmine methylsulfate | 0.005 |
| C | 1 | ϵ -Aminocaproic acid | 5 |
| | 2 | Allantoin | 0.3 |
| | 3 | Berberine chloride | 0.025 |
| | | Berberine sulfate | 0.025 |
| | 4 | Sodium azulene sulfonate | 0.02 |
| | 5 | Dipotassium glycyrrhizinate | 0.25 |
| | 6 | Zinc sulfate | 0.25 |
| Zinc lactate | | 0.25 | |
| 7 | Lysozyme chloride | 0.5 (potency) | |
| D | | Diphenhydramine hydrochloride | 0.05 |
| | | Chlorpheniramine maleate | 0.03 |
| E | 1 | Sodium flavine adenine dinucleotide | 0.05 |
| | 2 | Cyanocobalamin | 0.02 |
| | 3 | Retinol acetate | 50,000 units/100 mL |
| | | Retinol palmitate | 50,000 units/100 mL |
| | 4 | Pyridoxine hydrochloride | 0.1 |
| | 5 | Panthenol | 0.1 |
| | | Calcium pantothenate | 0.1 |
| Sodium pantothenate | | 0.1 | |
| 6 | Tocopherol acetate | 0.05 | |
| F | 1 | Potassium L-aspartate | 1 |
| | | Magnesium L-aspartate | 1 |
| | | Mixture of magnesium L-aspartate and potassium L-aspartate (equal mixture) | 2 |
| | 2 | Aminoethyl sulfonic acid | 1 |
| | 3 | Sodium chondroitin sulfate | 0.5 |

| | | | |
|---|-----------------|-------------------------------|-----|
| G | | Sulfamethoxazole | 4 |
| | | Sodium sulfamethoxazole | 4 |
| | | Sulfisoxazole | 4 |
| | | Sodium sulfisomidine | 5 |
| H | | Potassium chloride | -- |
| | | Calcium chloride | -- |
| | | Sodium chloride | -- |
| | | Sodium bicarbonate | -- |
| | | Sodium carbonate | -- |
| | | Dried sodium carbonate | -- |
| | | Magnesium sulfate | -- |
| | | Sodium hydrogen phosphate | -- |
| | | Monobasic sodium phosphate | -- |
| | | Monobasic potassium phosphate | -- |
| I | 1 | Polyvinyl alcohol | 2 |
| | | Polyvinylpyrrolidone | 2.5 |
| | 2 | Hydroxyethyl cellulose | -- |
| | | Hydroxypropylmethyl cellulose | -- |
| | | Glucose | -- |
| | Methylcellulose | -- | |
| J | | Alkylpolyaminoethylglycine | 0.1 |
| | | Boric acid | 2 |

Table II

| | |
|---------------------------------------|---|
| 1 (general ophthalmic drops) | Eyestrain, redness of the conjunctiva, prevention of eye troubles (after swimming, or to wash out sweat or dust etc.) , ophthalmia by ultraviolet rays etc. (snow blindness etc.), blepharitis (running eye), foreign-body feeling by contact lenses, itchy eyes, blurred vision (eye mucus) |
| 2 (antibiotic ophthalmic drops) | Conjunctivitis (pink-eye), chalazia, blepharitis (running eye), itchy eyes |
| 3 (Artificial tears) | Eyestrain, prevention of dry-eyes, foreign-body feeling by contact lenses, blurred vision (eye mucus) |
| 4 (eye-lotions for contact lenses) | Help to wear hard contact lenses or soft contact lenses |
| 5 (eye washes) | Irrigation of eyes, prevention of eye troubles (after swimming, or to wash out sweat or dust etc.) |

Feb 1, 1985
Notification PB No.90
Final revision Mar 22, 1995

The Standards for Marketing Approval of Vitamin Preparations

1. Scope of Vitamin Preparations

Vitamin Preparations, as defined here, are oral vitamin preparations which contain one or more vitamins for the purpose of alleviating symptoms against which such a vitamin should be effective or for vitamin supplementation.

2. Standards

The following standards shall be applied to Vitamin Preparations.

For vitamin preparations which do not conform to these standards, the submission of documents regarding the efficacy, safety, and the basis for combination shall be required for review.

(1) Types of Active Ingredients

- A) The types of active ingredients which may be combined in vitamin preparations are listed in the attached Table 1.
- B) For preparations mainly consisting of the active ingredients listed in Column I of the attached Table 1 (hereinafter referred to as Vitamin A preparations), those mainly consisting of the active ingredients in Group 1 may include the active ingredients listed in Column II or IV of the same Table and those mainly consisting of the active ingredients in Group 2 may include the active ingredients in Group 1 of Column I, Column III, IV, or VIII.
- C) Preparations mainly consisting of the active ingredients listed in Column II of the attached Table 1 (hereinafter referred to as Vitamin D preparations) may include the active ingredients listed in Group 1 of Column I, Column III, VIII, or Group 7 of Column X of the same Table.
- D) Preparations mainly consisting of the active ingredients listed in Column III of the attached Table 1 (hereinafter referred to as Vitamin E preparations) may include the active ingredients listed in Column IV, Group 2 of Column V, Column VI, VII, VIII, Group 1 or 2 of Column IX, Group 2, 3, 6, or 9 of Column X, or Group 1 or 2 of Column XI of the same Table.
- E) Preparations mainly consisting of the active ingredients listed in Column IV of the attached Table 1 (hereinafter referred to as Vitamin B₁ preparations) may include the active ingredients listed in Column III, V, VI, VII, Group 1 or 2 of Column IX, Group 1, 6, or 9 of Column X, or Group 1 of Column XI of the same Table.
- F) Preparations mainly consisting of the active ingredients listed in Column V of the attached Table 1 (hereinafter referred to as Vitamin B₂ preparations) may include the active ingredients listed in Column IV, VI, VIII, IX, Group 4, 5, 6, or 8 of Column X, or Group 3 of Column XI of the same Table.
- G) Preparations mainly consisting of the active ingredients listed in Column VI of the attached Table 1 (hereinafter referred to as Vitamin B₆ preparations) may include the active ingredients listed in Column III, IV, V, VII, VIII, IX, Group 4, 5, 6, or 8 of Column X, or Group 3 of Column XI of the same Table.
- H) Preparations mainly consisting of the active ingredients listed in Column VIII of the attached Table 1 (hereinafter referred to as Vitamin C preparations) may include the active ingredients listed in Column III, V, VI, IX, or Group 4, 5, or 8 of Column X of the same Table.
- I) Preparations mainly consisting of the active ingredients in Group 1 of Column I and Column II of the attached Table 1 (hereinafter referred to as Vitamin A and D preparations) may include the active ingredients listed in Column III, IV, VIII, or Group 7 of Column X of the same Table.
- J) Preparations mainly consisting of the active ingredients listed in Columns V and VI of the attached Table 1 (hereinafter referred to as Vitamin B₂ and B₆ preparations) may include the

active ingredients listed in Column VIII, IX, Group 4, 5, or 8 of Column X, or Group 3 of Column XI of the same Table.

- K) Preparations mainly consisting of the active ingredients listed in Columns III and VIII of the attached Table 1 (hereinafter referred to as Vitamin E and C preparations) may include the active ingredients listed in Group 2 of Column V, Column VI, Group 1 or 2 of Column IX, or Group 3 of Column X of the same Table.
- L) Preparations mainly consisting of the active ingredients listed in Columns IV, VI, and VII of the attached Table 1 (hereinafter referred to as Vitamin B₁, B₆ and B₁₂ preparations) may include the active ingredients listed in Column III, Group 1 or 2 of Column IX, or Group 6 of Column X of the same Table.
- M) If active ingredients from Column II, III, IV, V, VI, or VII of the attached Table 1 are combined, only one active ingredient from each column may be used.
- N) If active ingredients from Column VIII of the attached Table 1 are combined, no more than 2 active ingredients from the column may be used.
- O) If active ingredients from Column I, IX, or Group 4 or 8 of Column X of the attached Table 1 are combined, only one active ingredient from each column or group may be used.

(2) Quantities of active ingredients

- A) When the active ingredients in the attached Table 1 are used as the main ingredients of vitamin preparations, the maximum daily dose, minimum daily dose, maximum single dose, and minimum single dose shall be those given in Section A of the Table.
- B) When the active ingredients in the attached Table 1 in vitamin preparations are used as active ingredients other than the main vitamins, the maximum daily dose, minimum daily dose, and maximum single dose shall be those given in Section B of the Table.
- C) When 2 of the active ingredients in Column I or VIII of the attached Table 1 are combined or when 2 or more of the active ingredients in Group 7 of Column X are combined, the sum of the values obtained by dividing the amounts of each active ingredient used by their respective maximum daily dose shall not exceed one, or the sum of the values obtained by dividing the amounts of each active ingredient used by their respective minimum daily dose should be at least one.

(3) Dosage forms

The dosage forms of vitamin preparations shall be capsules, granules, pills, powders, electuaries, tablets, jelly type drops, or oral liquids.

(4) Dosage and administration

- A) In principle, the dosage of vitamin preparations shall not exceed 3 doses a day.
- B) Dosage and administration suggesting that the preparations may be given to infants less than 3 months of age are not permitted.
- C) Hard capsules and soft capsules, pills or tablets over 6 mm in diameter intended to be taken by children less than 5 years old are not permitted.
- D) Soft capsules, pills or tablets not more than 6 mm in diameter intended to be taken by children less than 3 years old are not permitted.
- E) The maximum and minimum daily and single doses for people under 15 years of age shall be calculated by multiplying the maximum and minimum daily and single doses shown in the attached Table 1 by the values specified in the Coefficient column for the corresponding age ranges in the attached Table 2.

(5) Indications

The indications of vitamin preparations should be within the scope of the attached Table 3.

Attached Table 1

| Classification | Active ingredient | A | | B | | Remarks | |
|----------------|--|------------------------------------|--------------------|--------------------|--------------------|--|---|
| | | Maximum daily dose | Minimum daily dose | Maximum daily dose | Minimum daily dose | | |
| Column I | Group 1 | Retinol acetate | 4,000I.U. | 2,000I.U. | 2,000I.U. | 500I.U. | as vitamin A |
| | | Retinol palmitate | 4,000I.U. | 2,000I.U. | 2,000I.U. | 500I.U. | as vitamin A |
| | | Vitamin A oil | 4,000I.U. | 2,000I.U. | 2,000I.U. | 500I.U. | as vitamin A |
| | Group 2 | Cod liver oil | 4,000I.U. | 2,000I.U. | 2,000I.U. | 500I.U. | as vitamin A |
| | | Strong cod liver oil | 4,000I.U. | 2,000I.U. | 2,000I.U. | 500I.U. | as vitamin A |
| Column II | Ergocalciferol | 400I.U. | 200I.U. | 200I.U. | 50I.U. | as vitamin D | |
| | Cholecalciferol | 400I.U. | 200I.U. | 200I.U. | 50I.U. | as vitamin D | |
| Column III | <i>d</i> - α -Tocopherol succinate | 300mg (100mg) | 100mg (50mg) | 100mg | 10mg | as <i>d</i> / α -tocopherol succinate | |
| | <i>dl</i> - α -Tocopherol succinate | 300mg (100mg) | 100mg (50mg) | 100mg | 10mg | | |
| | <i>dl</i> - α -Tocopherol calcium succinate | 300mg (100mg) | 100mg (50mg) | 100mg | 10mg | | |
| | <i>d</i> - α -Tocopherol acetate | 300mg (100mg) | 100mg (50mg) | 100mg | 10mg | | |
| | <i>dl</i> - α -Tocopherol acetate | 300mg (100mg) | 100mg (50mg) | 100mg | 10mg | | |
| | <i>d</i> - α -Tocopherol | 300mg (100mg) | 100mg (50mg) | 100mg | 10mg | | |
| | <i>dl</i> - α -Tocopherol | 300mg (100mg) | 100mg (50mg) | 100mg | 10mg | | |
| Column IV | Group 1 | Thiamine hydrochloride | 30mg (10mg) | 1mg (1mg) | 25mg (10mg) | 1mg | |
| | | Thiamine nitrate | 30mg (10mg) | 1mg (1mg) | 25mg (10mg) | 1mg | |
| | | Bisthiamine nitrate | 30mg (10mg) | 1mg (1mg) | 25mg (10mg) | 1mg | as thiamine disulfide |
| | | Thiamine disulfide | 30mg (10mg) | 1mg (1mg) | 25mg (10mg) | 1mg | |
| | | Thiamine dicetylsulfate | 30mg (10mg) | 1mg (1mg) | 25mg (10mg) | 1mg | as thiamine nitrate or thiamine hydrochloride |
| | Group 2 | Dicethiamine hydrochloride | 100mg | 5mg | 25mg | 1mg | as thiamine hydrochloride |
| | | Fursultiamine hydrochloride | 100mg | 5mg | 25mg | 1mg | as fursultiamine |
| | | Octothiamine | 100mg | 5mg | 25mg | 1mg | |
| | | Cycothiamine | 100mg | 5mg | 25mg | 1mg | |
| | | Bisibuthiamine | 100mg | 5mg | 25mg | 1mg | |
| | | Bisbentiamine | 100mg | 5mg | 25mg | 1mg | as thiamine hydrochloride |
| | | Fursultiamine | 100mg | 5mg | 25mg | 1mg | |
| | | Prosultiamine | 100mg | 5mg | 25mg | 1mg | |
| | Benfotiamine | 100mg | 5mg | 25mg | 1mg | as thiamine hydrochloride | |
| Column V | Group 1 | Flavin adenine dinucleotide sodium | 45mg | 5mg | 12mg | 2mg | as flavin adenine dinucleotide |
| | | Riboflavin | 30mg | 2mg | 12mg | 2mg | |
| | | Riboflavin sodium phosphate | 30mg | 2mg | 12mg | 2mg | as riboflavin |
| | Group 2 | Riboflavin butyrate | 20mg | 5mg | 12mg | 2mg | |

| | | | | | | | |
|-------------|----------------------------|--|---------|---------|---------|-------|---------------------|
| Column VI | | Pyridoxine hydrochloride | 100mg | 10mg | 50mg | 5mg | |
| | | Pyridoxal phosphate | 60mg | 10mg | 50mg | 5mg | |
| Column VII | | Hydroxocobalamin hydrochloride | 1,500µg | 60µg | 60µg | 1µg | as hydroxocobalamin |
| | | Hydroxocobalamin acetate | 1,500µg | 60µg | 60µg | 1µg | as hydroxocobalamin |
| | | Cyanocobalamin | 1,500µg | 60µg | 60µg | 1µg | |
| | | Hydroxocobalamin | 1,500µg | 60µg | 60µg | 1µg | |
| Column VIII | | Ascorbic acid | 2,000mg | 50mg | 500mg | 50mg | |
| | | Calcium ascorbate | 2,000mg | 50mg | 500mg | 50mg | as ascorbic acid |
| | | Sodium ascorbate | 2,000mg | 50mg | 500mg | 50mg | as ascorbic acid |
| Column IX | Group 1 | Nicotinic acid | / | / | 60mg | 12mg | |
| | | Nicotinamide | | | 60mg | 12mg | |
| | Group 2 | Panthenol | | | 30mg | 5mg | |
| | | Calcium pantothenate | | | 30mg | 5mg | |
| | | Sodium pantothenate | | | 30mg | 5mg | |
| | Group 3 | Biotin | | | 500µg | 10µg | |
| Column X | Group 1 | Mixture of potassium aspartate and magnesium aspartate (equal mixture) | | | 400mg | 200mg | |
| | Group 2 | Inositol hexanicotinate | | | 400mg | 80mg | |
| | Group 3 | Ursodeoxycholic acid | | | 60mg | 10mg | |
| | Group 4 | L-Cysteine hydrochloride | | | 160mg | 30mg | |
| | | L-Cysteine | | | 160mg | 30mg | |
| | Group 5 | Orotic acid | | | 200mg | 60mg | |
| | Group 6 | γ-Oryzanol | | | 10mg | 5mg | |
| | Group 7 | Calcium glycerophosphate | | | 300mg | 30mg | as calcium |
| | | Calcium gluconate | | | 300mg | 30mg | as calcium |
| | | Precipitated calcium carbonate | | | 300mg | 30mg | as calcium |
| | | Calcium lactate | | | 300mg | 30mg | as calcium |
| | | Anhydrous dibasic calcium phosphate | | | 300mg | 30mg | as calcium |
| | Group 8 | Dibasic calcium phosphate | | | 300mg | 30mg | as calcium |
| | | Glucuronolactone | | | 1,000mg | 200mg | |
| Group 9 | Glucuronamide | | | 1,000mg | 200mg | | |
| | Sodium chondroitin sulfate | | | 900mg | 180mg | | |

| | | | | | | |
|-----------|---------|-----------------------|--|---|-------|------|
| Column XI | Group 1 | Processed Garlic Bulb | | / | 200mg | 20mg |
| | Group 2 | Ginseng | Extract (Crude drug conversion value) | | 3g | 0.6g |
| | | | Powder | | 1.5g | 0.3g |
| | Group 3 | Coix seeds | Extract (Crude drug conversion value) | | 10g | 1g |
| | | | Powder | | 3g | 0.3g |

(Note) The figures in parentheses in the maximum daily dose or minimum daily dose columns indicate the maximum or minimum single dose, respectively.

Attached Table 2

| Age | Coefficient | |
|-------------------------|-------------|-------|
| 15 years old and over | 1 | (1) |
| 11 years old-Under 15 | 2/3 | (2/3) |
| 7 years old-Under 11 | 1/2 | (2/3) |
| 3 years old-Under 7 | 1/3 | (1/2) |
| 1 year old-Under 3 | 1/4 | (1/2) |
| 6 months-Under 1 | 1/5 | (1/2) |
| 3 months-Under 6 months | 1/6 | (1/2) |

(Note) The coefficients in parentheses are used for the active ingredients in Columns I and II for vitamins A, D, and A and D preparations.

Attached Table 3

| Preparations | | Indications |
|------------------------|---------------------------------------|---|
| Vitamin A preparations | Preparations with Group 1 ingredients | Relief of the following symptoms: dryness of the eyes Night blindness (nyctalopia) Supplementation of Vitamin A in the following cases: during pregnancy and lactation, decreased strength during and after illness, and for growing children |
| | Preparations with Group 2 ingredients | Relief of the following symptoms: dryness of the eyes Night blindness (nyctalopia) Supplementation of Vitamin A and D in the following cases: during pregnancy and lactation, decreased strength during and after illness, and for growing children and the elderly |
| Vitamin D preparations | | To treat bone and teeth developmental defects Prevention of rickets Supplementation of Vitamin D in the following cases: during pregnancy and lactation, and for growing children and the elderly |

| Preparations | Indications |
|--|--|
| Vitamin E preparations | <p>Relief of the following symptoms due to peripheral circulatory disturbances: stiffness in the shoulder and neck, numbness/chills in the limbs and chilblains</p> <p>Relief of the following symptoms in the climacterium: stiffness in the shoulder and neck, chills, numbness in the limbs and hot flashes, irregular menstruation (A physician or pharmacist should be consulted if there is no improvement after about one month of administration)</p> <p>Supplementation of Vitamin E in the following case: for the elderly</p> |
| Vitamin B ₁ preparations | <p>Relief of the following symptoms: neuralgia, muscle and joint pain (lumbago, stiff shoulder, frozen shoulder), numbness in the limbs, constipation, and eye strain</p> <p>Beriberi (A physician or pharmacist should be consulted if there is no improvement after about one month of administration)</p> <p>Supplementation of Vitamin B₁ in the following cases: physical fatigue, during pregnancy and lactation, decreased strength during and after illness</p> |
| Vitamin B ₂ preparations | <p>Relief of the following symptoms: angular stomatitis, canker sores, stomatitis, glossitis, eczema, dermatitis, rash, sores, acne, skin roughness, rosacea, congestion of the eye, and itchy eyes (A physician or pharmacist should be consulted if there is no improvement after about one month of administration)</p> <p>Supplementation of Vitamin B₂ in the following cases: physical fatigue, during pregnancy and lactation, and decreased strength during and after illness</p> |
| Vitamin B ₆ preparations | <p>Relief of the following symptoms: angular stomatitis, canker sores, stomatitis, glossitis, eczema, dermatitis, rash, sores, acne, skin roughness, and numbness in the limbs (A physician or pharmacist should be consulted if there is no improvement after about one month of administration)</p> <p>Supplementation of Vitamin B₆ in the following cases: during pregnancy and lactation, and decreased strength during and after illness</p> |
| Vitamin C preparations | <p>Relief of the following symptoms: spots, freckles, and pigmentation due to sunlight/rash</p> <p>Prevention of bleeding in the following cases: bleeding of the gums and nose bleeds (A physician, pharmacist, or dentist should be consulted if there is no improvement after about one month of administration)</p> <p>Supplementation of Vitamin C in the following cases: physical fatigue, during pregnancy and lactation, decreased strength during and after illness, and for the elderly</p> |
| Vitamin A and D preparations | <p>Relief of the following symptoms: dryness of the eyes</p> <p>Bone and teeth developmental defects</p> <p>Night blindness (nyctalopia)</p> <p>Prevention of rickets</p> <p>Supplementation of Vitamin A and D in the following cases: during pregnancy and lactation, decreased strength during and after illness, and for growing children and the elderly</p> |
| Vitamin B ₂ and B ₆ preparations | <p>Relief of the following symptoms: angular stomatitis, canker sores, stomatitis, glossitis, eczema, dermatitis, rash, sores, acne, and skin roughness (A physician or pharmacist should be consulted if there is no improvement after about one month of administration)</p> <p>Supplementation of Vitamin B₂ and B₆ in the following cases: physical fatigue, during pregnancy and lactation, and decreased strength during and after illness</p> |

| Preparations | Indications |
|--|--|
| Vitamin E and C preparations | <p>Relief of the following symptoms due to peripheral circulatory disturbances: stiffness in the shoulder and neck, numbness/chills in the limbs and chilblains</p> <p>Relief of the following symptoms: spots, freckles, and pigmentation due to sunlight/rash</p> <p>Prevention of bleeding in the following cases: bleeding of the gums and nose bleeds (A physician, pharmacist, or dentist should be consulted if there is no improvement after about one month of administration)</p> <p>Supplementation of Vitamin E and C in the following cases: physical fatigue, decreased strength during and after illness, and for the elderly</p> |
| Vitamin B ₁ , B ₆ , and B ₁₂ preparations | <p>Relief of the following symptoms: neuralgia, muscle and joint pain (lumbago, stiff shoulder, frozen shoulder), numbness in the limbs, and eye strain (A physician or pharmacist should be consulted if there is no improvement after about one month of administration)</p> <p>Supplementation of Vitamin B₁, B₆, and B₁₂ in the following cases: physical fatigue, during pregnancy and lactation, and decreased strength during and after illness</p> |

Provisional Translation
from Japanese Original

Feb 1, 1988
Notification PB No.94
Final revision May 15, 1998

The Standards for Marketing Approval of Enemas

1. Scope of Enemas

The scope of preparations subject to these standards covers medicines for rectal application formulated with the intent of treating constipation.

2. Approval Standards

The approval standards for enemas are as follows.

For preparations not conforming to these standards, efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- (a) The types of active ingredients that may be used are those listed in Table 1 for liquid preparations and those listed in Table 2 for suppositories.
- (b) The active ingredients that must be included are those from Column I of Table 1 and Column I or II of Table 2.
- (c) The active ingredients from Column II of Table 1 can be combined with the active ingredients from Column I.
- (d) The active ingredients from Columns I and II of Table 2 may not be used in the same preparation.

(2) Quantities of Active Ingredients

- (a) The maximum and minimum single doses of the active ingredients in Tables 1 and 2 are those specified in the respective tables.
- (b) The concentration of glycerin in Column I of Table 1 for liquid preparations is 42% to 50%.

(3) Dosage Form

The dosage forms are liquids and suppositories.

(4) Dosage and Administration

(a) Liquid preparations

- [1] When dilution is required, water should be added so that the concentration of glycerin reaches 42% to 50%.
- [2] When no effect is obtained by intra-rectal administration of a single dose of the preparation, administer the same amount again.

(b) Suppositories

If no effect is obtained by the insertion of a single suppository, insert 1 more. In the case of suppositories containing ingredients from Column II of Table 2, the daily dose is limited to 0.02 g.

- (c) Dosages for children under 3 years of age is not approved.

- (d) For children under 12 years of age, the single dose of the active ingredients in Table 1 is that obtained by multiplying the single doses listed in the table by the coefficient for the corresponding age range in Table 3. The single dose of the active ingredients from Column I of Table 2 is that obtained by multiplying the single doses listed in the table by the coefficient in Table 4. The single dose of the active ingredients from Column II of Table 2 is that obtained by multiplying the single doses listed in the table by the coefficient in Table 5.

(5) Indications

The indication is limited to constipation.

Table 1

Liquids

| Column | Active ingredient | Single dose (g) | |
|--------|-------------------|-----------------|---------|
| | | Minimum | Maximum |
| I | Glycerin | 12 | 18 |
| II | D-Sorbitol | - | 10 |

Table 2

Suppositories

| Column | Active ingredient | Single dose (g) | |
|--------|-------------------|-----------------|---------|
| | | Minimum | Maximum |
| I | Glycerin | 1.5 | 2.5 |
| II | Bisacodyl | 0.005 | 0.01 |

Table 3

| Age | Coefficient |
|----------------------------|-------------|
| 12 years of age or over | 1 |
| 6 to under 12 years of age | 2/3 |
| 1 to under 6 years of age | 1/3 |
| Under 1 year of age | 1/6 |

Table 4

| Age | Coefficient |
|----------------------------|-------------|
| 12 years of age or over | 1 |
| 3 to under 12 years of age | 2/3 |

Table 5

| Age | Coefficient |
|----------------------------|-------------|
| 12 years of age or over | 1 |
| 6 to under 12 years of age | 1/2 |
| 3 to under 6 years of age | 1/5 |

Provisional Translation
from Japanese Original

Mar 28, 1989
Notification PB No.300
Final revision May 15, 1998

The Standards for Marketing Approval of Anthelmintics

1. Scope of Anthelmintics

The scope of preparations subject to these standards covers all oral preparations intended to eradicate parasites (Kampo medicine* formulas are not covered).

* Kampo medicine is traditional Japanese medicine.

2. Approval Standards

The approval standards for anthelmintics are as follows.

For preparations not conforming to these standards, efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- (a) The types of active ingredients that may be used are shown in Table 1.
- (b) One or more of the active ingredients from Column A of Table 1 must be included.
- (c) Preparations mainly containing active ingredients from Group 1 of Column A in Table 1 may include active ingredients from Column B or C.
- (d) Preparations mainly containing active ingredients from Group 2a of Column A in Table 1 may include active ingredients from Column B.
- (e) Preparations mainly containing active ingredients from Group 2b of Column A in Table 1 may include active ingredients from Group 2 of Column B, or Column D. However, the active ingredient from Group 2 of Column D may be included only when an active ingredient from Group 2 of Column B is also included.
- (f) Preparations mainly containing active ingredients from Group 3 of Column A or Group 4 of Column A in Table 1 may not include any other active ingredient.
- (g) Preparations mainly containing active ingredients from Groups 1 and 2 of Column A, those mainly containing active ingredients from Groups 1 and 3 of Column A, and those mainly containing active ingredients from Groups 1, 2, and 3 of Column A in Table 1 may also include active ingredients from Column B or C.
- (h) In the case of Columns B and C in Table 1, only 1 active ingredient from each column may be used in the preparation.
- (i) Only 1 active ingredient from Group 2 of Column A in Table 1 may be included from this group.

(2) Quantities of Active Ingredients

- (a) The maximum daily dose of each of the active ingredients in Table 1 is the amount shown in this table.
- (b) When an active ingredient from Group 1 of Column A in Table 1 is combined

with another active ingredient from Column A, or when active ingredients from Group 1 of Column B in Table 1 are combined, the lower limit of the daily dose is half of the maximum daily dose.

- (c) When an active ingredient from Group 2 of Column A in Table 1 is combined with another active ingredient from Column A, the lower limit of the daily dose is 1/4th of the maximum daily dose.
- (d) When an active ingredient from Group 3 of Column A in Table 1 is combined with another active ingredient from Column A, the lower limit of the daily dose is 3/4 of the maximum daily dose.
- (e) The lower limit of the daily dose of the active ingredients from Group 4 of Column A in Table 1 is 2/5th of the maximum daily dose.
- (f) The lower limit of the daily dose of the active ingredients from Group 2 of Column B, and Column D of Table 1 is 1/10th of the maximum daily dose.
- (g) The lower limit of the daily dose of the active ingredients from Column C of Table 1 is 1/5th of the maximum daily dose.
- (h) When 2 or more of the active ingredients from Column A of Table 1 are combined, the lower limit of the daily dose of each active ingredient is 1/5th of the maximum daily dose, and the sum of the values obtained by dividing the amount of each active ingredient combined by its maximum daily dose must be at least half, and should not exceed 2/3.

However, when 2 or more of the active ingredients only from Group 3 of Column A are combined, the sum of the values obtained by dividing the amount of each active ingredient combined by its maximum daily dose should be at least 3/4 and not exceed 1.

- (i) When 2 or more of the active ingredients from Group 1 of Column D in Table 1 are combined, the sum of the values obtained by dividing the amount of each active ingredient combined by its maximum daily dose should not exceed 1.

(3) Dosage Form

The dosage forms are capsules, granules, pills, powders, tablets, decoctions (only preparations mainly containing the active ingredients from Group 2b of Column A in Table 1), chocolate tablets, and oral liquids.

(4) Dosage and Administration

(a) Dose regimen

- (i) Preparations mainly containing the active ingredients from Group 1 of Column A in Table 1
Take twice a day on an empty stomach, or take once before bed after a light evening meal and once on the following morning.
Do not take more than twice in succession.
- (ii) Preparations mainly containing the active ingredients from Group 2a of Column A in Table 1
Take once or twice a day on an empty stomach.
Do not take more than twice in succession.
- (iii) Preparations mainly containing the active ingredients from Group 2b of Column A in Table 1
Take once or twice a day on an empty stomach.
- (iv) Preparations mainly containing the active ingredients from Group 3 of Column A in Table 1
 - [1] For eradication of ascarids
Take once or twice a day on an empty stomach for 1 to 2 days.
Do not take for more than 2 successive days.
 - [2] For eradication of oxyurids

Take once or twice a day on an empty stomach for 1 week.

Do not take for more than 7 successive days.

- (v) Preparations mainly containing the active ingredients from Group 4 of Column A in Table 1

Take once a day.

Do not take more than twice in succession.

- (vi) Preparations mainly containing the active ingredients from Groups 1 and 2 of Column A, those mainly containing the active ingredients from Groups 1 and 3 of Column A, and those mainly containing the active ingredients from Groups 1, 2, and 3 of Column A in Table 1

Take once or twice a day on an empty stomach, or take once before bed after a light evening meal and once on the following morning.

Do not take more than twice in succession.

- (b) For decoctions, the method of preparation at the time of use should be clearly described.
- (c) Dosage for infants younger than 3 months of age is not approved.
- (d) For capsules, and pills and tablets larger than 6 mm in diameter, dosage for children under 5 years of age is not approved.
- (e) For pills and tablets, dosage for infants younger than 3 years of age is not approved, even if the diameter is less than 6 mm.
- (f) The maximum daily doses for children under 15 years of age are the amounts obtained by multiplying the maximum daily dose in Table 1 by the coefficients for the respective age groups shown in Table 2.

(5) Indications

- (i) Preparations mainly containing the active ingredients from Group 3 of Column A in Table 1

Eradication of ascarids and oxyurids

- (ii) Preparations mainly containing the active ingredients from Group 4 of Column A in Table 1

Eradication of oxyurids

- (iii) Other preparations

Eradication of ascarids

Table 1

| Classification | | Active ingredient | Maximum daily dose | | Remarks | |
|----------------|-------------------|----------------------------------|--------------------|--|--|--|
| Column A | Group 1 | Santonin | 200 mg | | | |
| | Group 2 | a | Kainic acid | 20 mg | | |
| | | b | Digenea | Powder | Extract (converted to the crude drug amount) | |
| | | | - | 10 g | | |
| | Group 3 | | | For ascarids | For oxyurids | |
| | | Piperazine adipate | 4000 mg | 2000 mg | As piperazine hexahydrate | |
| | | Piperazine citrate | 4000 mg | 2000 mg | As piperazine hexahydrate | |
| | | Piperazine hexahydrate | 4000 mg | 2000 mg | | |
| | | Piperazine malate | 4000 mg | 2000 mg | As piperazine hexahydrate | |
| | | Piperazine phosphate | 4000 mg | 2000 mg | As piperazine hexahydrate | |
| Group 4 | Pyrvinium pamoate | 250 mg | | As pyrvinium base | | |
| Column B | Group 1 | Sulfur | 1000 mg | | | |
| | | Magnesium oxide | 2000 mg | | | |
| | | Diethyl sodium sulfosuccinate | 200 mg | | | |
| | | Bisacodyl | 20 mg | | | |
| | Group 2 | | Powder | Extract (converted to the crude drug amount) | | |
| | | Aloes | 0.75 g | 0.75 g | | |
| | | Senna Leaf | 1.5 g | 6 g | | |
| | | Rhubarb | 3 g | 4 g | | |
| Column C | | Aminoethylsulfonic acid | 2000 mg | | | |
| | | Bile extract (powder) | 500 mg | | | |
| | | Bile powder | 1500 mg | | | |
| | | Dehydrocholic acid | 500 mg | | | |
| Column D | Group 1 | | Powder | Extract (converted to the crude drug amount) | | |
| | | Melia Bark | - | 10 g | | |
| | | Japanese Zanthoxylum Peel | - | 3 g | | |
| | | Rangoon Creeper Fruit | - | 3 g | | |
| | Group 2 | Glycyrrhiza | - | 3.3 g | | |

Table 2

| Age group | Coefficient |
|---------------------------------|-------------|
| 15 years of age and over | 1 |
| 11 to under 15 years of age | 2/3 |
| 8 to under 11 years of age | 1/2 |
| 5 to under 8 years of age | 1/3 |
| 3 to under 5 years of age | 1/4 |
| 1 to under 3 years of age | 1/5 |
| 3 months to under 1 year of age | 1/7 |

Provisional Translation
from Japanese Original

Feb 1, 1991
Notification PB No.109
Final revision Jan 19, 2012

The Standards for Marketing Approval of Nasal Drops for Rhinitis

1. Scope of Nasal Drops for Rhinitis

The scope of preparations subject to these standards covers intranasal medicines intended for the relief of symptoms of rhinitis.

2. Approval Standards

The approval standards for nasal drops for rhinitis are as follows.

For preparations not conforming to these standards, efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- a. The types of active ingredients that may be used are shown in Table 1.
- b. The active ingredients that must be included are those from Column I of Table 1.
- c. Active ingredients from different columns of Table 1 may be combined with each other.
- d. When the active ingredients from Column I, II, III, or IV of Table 1 are combined, only 1 ingredient per column is permitted.

(2) Quantities of Active Ingredients

- a. The maximum concentration of each of the active ingredients is shown in Table 1.
- b. The minimum concentration of each of the active ingredients from Column I of Table 1 is half of the respective maximum concentrations, and that of the active ingredients from the other columns is 1/5th of the respective maximum concentrations.

(3) Dosage Form

The dosage forms are intranasally-applied liquid preparations.

(4) Dosage and Administration

- a. Preparations are to be applied intranasally not more than 6 times a day. The application method and intervals must be clearly indicated. The application interval is to be at least 3 hours.
- b. Dosages for infants under 2 years of age are not approved.
- c. The maximum concentrations for children under 7 years of age are half of the maximum concentration shown in Table 1.

(5) Indications

The indications are to be within the following scope: relief of the following

symptoms due to acute rhinitis, allergic rhinitis or sinusitis; stuffy nose, runny nose (excessive nasal discharge), sneezing, dull headache (heaviness in head).

(6) Packaging Units

The maximum volume of containers for liquids is limited to 30 mL.

Table 1

| Classification | Active ingredient | Maximum concentration (%) |
|----------------|---|---------------------------|
| Column I | Epinephrine | 0.01 |
| | Ephedrine hydrochloride | 0.5 |
| | Tetrahydrozoline hydrochloride | 0.1 |
| | Naphazoline hydrochloride | 0.05 |
| | Phenylephrine hydrochloride | 0.5 |
| | <i>d,l</i> -Methylephedrine hydrochloride | 0.5 |
| | Tetrahydrozoline nitrate | 0.1 |
| | Naphazoline nitrate | 0.05 |
| Column II | Iproheptine hydrochloride | 0.5 |
| | Diphenhydramine hydrochloride | 0.2 |
| | Diphenhydramine | 0.2 |
| | Chlorpheniramine maleate | 0.5 |
| Column III | Acrinol | 0.05 |
| | Cetylpyridinium chloride | 0.05 |
| | Benzalkonium chloride | 0.02 |
| | Benzethonium chloride | 0.02 |
| Column IV | Lidocaine hydrochloride | 0.5 |
| | Lidocaine | 0.5 |
| Column V | Dipotassium glycyrrhizinate | 0.3 |
| | Methyl salicylate | 0.05 |

Provisional Translation
from Japanese OriginalMar 22, 1995
Notification PFSB No.277

The Standards for Marketing Approval of Antihemorrhoids (External Preparations)

1. Scope of Antihemorrhoids (External Preparations)

The scope of preparations subject to these standards covers medicines intended for the relief of hemorrhoidal symptoms in the anus and rectum (Kampo medicine* formulas and non-Kampo crude drug remedies consisting of crude drug only are not covered).

*Kampo medicine is traditional Japanese medicine.

2. Approval Standards

The approval standards for antihemorrhoids (external preparations) are as follows.

For preparations deviating from these standards, efficacy and safety data and reasons justifying the combination should be submitted, and the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- a. The types of active ingredients that may be combined are listed in Table 1.
- b. Active ingredients that must be included are those from Column I in Table 1.
- c. Active ingredients in different columns in Table 1 may be mutually combined, unless otherwise specified elsewhere.
- d. When active ingredients from Column II, III, V, or VI are to be combined, only 1 ingredient from each column is allowed.
- e. When active ingredients from Column VIII or IX are to be combined, only 1 ingredient from the same group is allowed.
- f. It is permissible to use 2 of the active ingredients from Group 1 in Column I of Table 1, but the combination of dibucaine hydrochloride with dibucaine and the combination of lidocaine hydrochloride with lidocaine are not permitted.
- g. In Column VII of Table 1, the combination of allantoin with aluminum chlorohydroxy allantoinate, that of dried aluminum potassium sulfate with aluminum potassium sulfate, and that of purified yolk lecithin with egg yolk oil is not permitted.

(2) Quantities of Active Ingredients

- a. The maximum concentration of each of the active ingredients listed in Table 1 is given in "A" for ointments to be applied by rubbing or external liquids. The maximum single dose of each of the active ingredients is given in "B" for ointments to be applied by an applicator and for suppositories.
- b. The minimum concentration or the lowest single dose of each of the active ingredients listed in the individual columns (except for the ingredients of Group 2 in Columns VII and IX) of Table 1 is 1/5th of the corresponding maximum concentration or the maximum single dose. However, if 1 or more of the active

ingredients from Column I is used, the concentration of at least 1 active ingredient must be at least half of the maximum concentration or the maximum single dose.

- c. The minimum concentration or the lowest single dose of each of the active ingredients listed in Group 2 of Columns VII and IX is 1/10th of the corresponding maximum concentration or maximum single dose.
- d. When 2 active ingredients listed in Group 1 of Column I in Table 1 are combined, the sum of the values obtained by dividing the individual concentrations or doses by their respective maximum concentration or maximum single dose must not exceed 1.

(3) Dosage Form

The dosage forms should be suppositories (including soft capsules), ointments, and external liquids (including aerosols).

(4) Dosage and Administration

a Ointments to be applied by rubbing and external liquids

The preparations should be applied to the anal area up to 3 times a day at maximum. For external liquids, the method of application should be indicated clearly.

b. Ointments to be applied by an applicator and suppositories

- [1] The preparations should be applied to the anal area or the rectum 1 dose at a time, up to 3 times a day, at maximum.
- [2] For ointments to be applied by an applicator, the method of application should be indicated clearly.
- [3] Dosage for children younger than 7 years of age is not approved.
- [4] The maximum single dose for those 7 to <15 years of age is half of the maximum single dose given in "B" of Table 1.

(5) Indications

The scope of indications is "Relief of pain, itching, swelling, bleeding, and erosion associated with bleeding piles (ripped piles)/blind piles, and disinfection. The indications of "erosion" and "disinfection" should be limited to ointments to be applied by rubbing and external liquids. The indications given in the upper column of the following table should be limited to cases in which 1 of the active ingredients from a group or column in the lower column of the following table is used at an amount not less than half of the maximum concentration or the maximum single dose as specified in Table 1.

| Upper column | Lower column |
|-----------------------|------------------------------|
| Itching | Group 1 of Column I, III, VI |
| Swelling and bleeding | Column II, III, IV |
| Erosion | Column IV |
| Disinfection | Group 1 of Column V |

Table 1

| Classification | | Active ingredient | A Maximum concentration (%) | B Maximum single dose (mg) |
|----------------------|-----------|---|-----------------------------|----------------------------|
| Column I | Group 1 | Ethyl aminobenzoate | 10 | 200 |
| | | Dibucaine hydrochloride | 0.5 | 10 |
| | | <i>p</i> -Butylaminobenzoyl diethylaminoethyl hydrochloride | 0.1 | 2 |
| | | Procaine hydrochloride | 2 | 40 |
| | | Meprylcaine hydrochloride | 0.5 | 10 |
| | | Lidocaine hydrochloride | 3 | 60 |
| | | Oxypolyethoxydodecane | 3 | 60 |
| | | Dibucaine | 0.5 | 10 |
| | | Mepivacaine | 0.75 | 15 |
| | Lidocaine | 3 | 60 | |
| | Group 2 | Scopolia Extract | 5 | 100 |
| Column II | | Epinephrine solution | 0.001 (as epinephrine) | - |
| | | Ephedrine hydrochloride | 1 | 20 |
| | | Tetrahydrozoline hydrochloride | 0.05 | 1 |
| | | Naphazoline hydrochloride | 0.05 | 1 |
| | | Phenylephrine hydrochloride | 0.25 | 5 |
| Column III | | <i>d</i> -Methylephedrine hydrochloride | 0.5 | 10 |
| | | Hydrocortisone acetate | 0.5 | 5 |
| | | Prednisolone acetate | 0.1 | 1 |
| | | Hydrocortisone | 0.5 | 5 |
| Column IV | | Prednisolone | 0.1 | 1 |
| | | Zinc oxide | 20 | 400 |
| Column V | Group 1 | Tannic acid | 5 | 100 |
| | | Acrinol | 0.2 | 4 |
| | | Alkyl polyaminoethylglycine | 0.2 | 4 |
| | | Isopropylmethylphenol | 0.1 | 2 |
| | | Cetylpyridinium chloride | 0.2 | 4 |
| | | Dequalinium chloride | 0.1 | 2 |
| | | Berberine chloride | 1.5 | 30 |
| | | Benzalkonium chloride | 0.1 | 2 |
| | | Chlorhexidine hydrochloride | 0.5 | 10 |
| | | Chlorhexidine gluconate solution | 1 | - |
| | Cetrimide | 0.125 | 2.5 | |
| | Resorcin | 2 | 40 | |
| | Group 2 | Sulfadiazine | 5 | 100 |
| | | Sulfisomidine | 5 | 100 |
| Sulfisomidine sodium | | 5 | 100 | |
| Homosulfamine | | 5 | 100 | |
| Column VI | Group 1 | Diphenylpyraline hydrochloride | 0.1 | 2 |
| | | Diphenhydramine hydrochloride | 1 | 20 |
| | | Diphenhydramine | 1 | 20 |
| | | Chorpheniramine maleate | 0.2 | 4 |
| | Group 2 | Crotamiton | 5 | 100 |

| | | | | | |
|-----------------------|---------|-------------------------------------|--|---------------------------|--|
| Column VII | Group 1 | Allantoin | 1 | 20 | |
| | | Aluminium chlorhydroxy allantoinate | 1 | 20 | |
| | | Ichthammol | 10 | 200 | |
| | | Lysozyme chloride | 1.5 (potency) | 30 (potency) | |
| | | Dried aluminum potassium sulfate | 1.1 | 22 | |
| | | Glycyrrhetic acid | 1.5 | 30 | |
| | | 1,4-Dimethyl-7-isopropylazulene | 0.04 | 0.8 | |
| | | Purified yolk lecithin | 5 | 100 | |
| | | Egg yolk oil | 5 | 100 | |
| | | Aluminum potassium sulfate | 2 | 40 | |
| | Group 2 | | Extract (converted to crude drug amount) | Powder | Extract (converted to crude drug amount) |
| Lithospermum root | | 2.5 | 2.5 | 50 | 50 |
| Horse Chestnut Seed | | 25 | — | 500 | — |
| Witch hazel leaf | | 25 | — | 500 | — |
| Processed Garlic Bulb | | 1 | 20 | | |
| Column VIII | Group 1 | Cod liver oil | 120,000 I.U./100 g (as vitamin A) | 2,400 I.U. (as vitamin A) | |
| | | Strong cod liver oil | 120,000 I.U./100 g (as vitamin A) | 2,400 I.U. (as vitamin A) | |
| | | Retinol palmitate | 120,000 I.U./100 g (as vitamin A) | 2,400 I.U. (as vitamin A) | |
| | | Vitamin A oil | 120,000 I.U./100 g (as vitamin A) | 2,400 I.U. (as vitamin A) | |
| | Group 2 | Tocopherol acetate | 3 | 60 | |
| | | Tocopherol | 3 | 60 | |
| Column IX | Group 1 | <i>d</i> -Camphor | 1 | 20 | |
| | | <i>dl</i> -Camphor | 1 | 20 | |
| | Group 2 | Mentha Oil | 0.75 | 15 | |
| | | <i>l</i> -Menthol | 0.5 | 10 | |
| | | <i>d</i> <i>l</i> -Menthol | 0.5 | 10 | |
| | Group 3 | Eucalyptus Oil | 0.5 | 10 | |

Provisional Translation
from Japanese Original

May 15, 1998
Notification PSB No.447

The Standards Marketing Approval of Athlete's Foot and Ringworm Remedies

1 Scope of Athlete's Foot and Ringworm Remedies

The scope of preparations subject to these standards covers external medicines intended for the relief of symptoms associated with athlete's foot and ringworm Kampo medicine* formulas and non-Kampo crude drug remedies consisting of crude drug only are not covered).

*Kampo medicine is traditional Japanese medicine.

2 Approval Standards

The approval standards for athlete's foot and ringworm remedies are as follows.

For preparations deviating from these standards, efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- a. The types of active ingredients that may be combined are listed in Table 1.
- b. At least 1 of the active ingredients from either Column I (apart from the ingredients in Groups 12 and 13) or Column II of Table 1 must be combined.
- c. Active ingredients in different columns listed in Table 1 may be mutually combined.
- d. When active ingredients from Column V of Table 1 are to be combined with other ingredients in the same Column, the use of only 1 ingredient is allowed.
- e. Up to 3 active ingredients from Column I of Table 1 may be used. However, with the exception of undecylenic acid and zinc undecylenate in Group 1, the use of only 1 ingredient from each group is allowed. Active ingredients marked with "△" must not be combined with the other ingredients in this column.
- f. When active ingredients from Group 1 of Column III or Group 1 of Column IV listed in Table 1 are to be combined, the use of only 1 ingredient from the same group is allowed.
- g. Up to 3 active ingredients from Group 2 of Column III listed in Table 1 may be used. However, acetic acid should not be combined with the other ingredients in this group.
- h. In Column VI, the combination of allantoin with aldioxa and the combination of glycyrrhizinic acid or its salts with glycyrrhetic acid are not permitted. In Column VII, the combination of *d*-camphor with *dl*-camphor and the combination of mentha oil with *dl*-menthol and *l*-menthol are not permitted.

(2) Quantities of Active Ingredients

- a. The maximum concentration of each of the active ingredients is shown in Table 1.
- b. The minimum concentration of individual active ingredients listed in Column I (except for Groups 12 and 13) and Column II of Table 1 is 1/5th of the maximum.

concentration (for ingredients with a concentration in parentheses, the minimum concentration is 1/5th of the one in the parentheses). In this case, the concentration of 1 or more ingredients must be at least half of the specified maximum concentration (for ingredients with concentrations in parentheses, the minimum concentration must be the one provided in parentheses).

- c. The minimum concentration of individual active ingredients listed in Groups 12 and 13 of Column I and those listed in Columns III, IV, V, VI, VII, VIII, and IX of Table 1 is 1/10th of the maximum concentration. However, in the case of benzalkonium chloride in Group 1 of Column III, the concentration must be as listed in the maximum concentration column.

(3) Dosage Form

The dosage forms are aerosols, ointments, external liquids, and external powders.

(4) Dosage and Administration

Preparations should be applied to the skin surface several times a day. The method of application should be clearly indicated.

(5) Indications

The indications are to be within the scope of "athlete's foot, jock itch, and ringworm."

Table 1

| Classification | Active ingredient | Maximum concentration (%) | |
|----------------|---|----------------------------------|------------------------|
| Column I | Group 1 | Undecylenic acid | 10 |
| | | Zinc undecylenate | 20 |
| | | △ Phenyl-11-iodo-10-undecynoate | 0.5 |
| | Group 2 | △ Exalamide | 5 |
| | Group 3 | △ Clotrimazole | 1 |
| | | △ Econazole nitrate | 1 |
| | | △ Miconazole nitrate | 1 |
| | | △ Tioconazole | 1 |
| | Group 4 | △ Zinc diethyldithiocarbamate | 25 |
| | Group 5 | △ Ciclopirox olamine | 1 |
| | Group 6 | △ Siccamin | 1 (potency) |
| | | △ Trichomycin | 15,000,000 units/100 g |
| | | △ Pyrrolnitrin | 0.5 (potency) |
| Group 7 | Thianthol | 30 | |
| Group 8 | 2,3,6-Tribromphenol caproate | 2 | |
| Group 9 | Trimethylcetylammonium pentachlorophenate | 2 | |
| Group 10 | △ Tolciclate | 1 | |
| | Tolnaftate | 2 | |
| Group 11 | △ Haloprogin | 1 | |
| Group 12 | Sulfur | 10 | |
| Group 13 | Hibiscus syriacus bark (converted to the crude drug amount) | 10 | |
| Column II | Group 1 | Salicylic acid | 10 (2) |
| | Group 2 | Zinc oxide | 60 (2) |
| Column III | Group 1 | Acrinol | 0.2 |
| | | Alkylpolyaminoethyl glycine | 1 |
| | | Berberine benzoate | 0.5 |
| | | Isopropylmethylphenol | 3 |
| | | Dequalinium chloride | 0.5 |
| | | Benzalkonium chloride | 0.05 |
| | | Benzethonium chloride | 0.5 |
| | | Chlorhexidine hydrochloride | 1 |
| | | Chlorhexidine gluconate solution | 2.5 |
| | | Dequalinium acetate | 1 |
| | | Hinokitiol | 0.1 |
| | Resorcin | 5 | |
| | Group 2 | Benzoic acid | 12 |
| | | Chlorobutanol | 1 |
| | | Acetic acid | 2 |
| | | Phenol | 2 |
| | | Iodine tincture | 20 |

| | | | |
|-------------|---|--|------|
| Column IV | Group 1 | Diphenylpyraline hydrochloride | 0.2 |
| | | Diphenhydramine hydrochloride | 2 |
| | | Chlorpheniramine | 0.5 |
| | | Diphenhydramine salicylate | 2 |
| | | Diphenylimidazole | 0.2 |
| | | Diphenhydramine | 1 |
| | | Chlorpheniramine maleate | 0.5 |
| | Group 2 | Crotamiton | 10 |
| Column V | | Ethyl aminobenzoate | 6 |
| | | Dibucaine hydrochloride | 0.5 |
| | | Procaine hydrochloride | 2 |
| | | Lidocaine hydrochloride | 2.5 |
| | | Oxypolyethoxydodecane | 3 |
| | | Dibucaine | 0.5 |
| | | Lidocaine | 2.5 |
| Column VII | Group 1 | Allantoin | 1 |
| | | Aldioxa | 0.2 |
| | | Ichthammol | 6 |
| | | Glycyrrhizinic acid and its salts | 1 |
| | | Glycyrrhetic acid | 1 |
| | | Methyl salicylate | 2.5 |
| | | Dimethyl isopropylazulene | 0.04 |
| | Group 2 | Lithospermum root (converted to the crude drug amount) | 6 |
| | Japanese angelica root (converted to the crude drug amount) | 6 | |
| Column VII | | <i>d</i> -Camphor | 4 |
| | | <i>d</i> ^l -Camphor | 4 |
| | | Thymol | 2.5 |
| | | Mentha oil | 0.5 |
| | | <i>d</i> ^l -Menthol | 3 |
| | | <i>d</i> ^l -Menthol | 3 |
| | | <i>d</i> -Borneol | 5 |
| Column VIII | | Urea | 10 |
| | | Diethyl phthalate | 25 |
| Column IX | | Aluminum hydroxychloride | 10 |

Provisional Translation
from Japanese Original

Nov 1, 2011
Notification PFSB No.1101-1

The Standards for Marketing Approval of Antipruritic and Anti-inflammatory Drugs

1. Scope of Antipruritic and Anti-inflammatory Drugs

The scope of preparations subject to these standards covers medicines mainly containing adrenocortical hormones or antihistamines for dermal application formulated with the intent of using as antipruritic and anti-inflammatory drugs.

2. Approval Standards

The approval standards for antipruritic and anti-inflammatory drugs are as follows: For antipruritic and anti-inflammatory drugs mainly containing adrenocortical hormones or antihistamines that do not conform to these standards, efficacy and safety data and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

(1) Types of Active Ingredients

- a) The active ingredients that may be combined in the preparations are shown in the Table.
- b) At least 1 ingredient from either Column I or Column II of the Table must be combined.
- c) Preparations mainly containing the active ingredients from Column I of the Table may include the active ingredients from Column II, III, IV, V, VI, VII, VIII, IX, X, or XII.
- d) Preparations mainly containing the active ingredients from Column II of the Table may include the active ingredients from Column III, IV, V, VI, VII, VIII, IX, X, XI, or XII.
- e) In the case of Column I, II, IV, V, VII, VIII, or IX in the Table, only 1 active ingredient from each column may be used in a preparation. When the active ingredient from Group 1 or 2 of Column X, or Group 1 or 3 of Column XII is combined, only 1 active ingredient from each group may be used in a preparation.

(2) Quantities of Active Ingredients

- a) The maximum concentration of each of the active ingredients in the Table is that shown in the table.
- b) The minimum concentration of each of the active ingredients listed in Columns II, III, V, VI, VIII, Groups 2 and 3 of Column X, Column XI, and Group 2 of Column XII is 1/5th of the maximum concentration (for ingredients with a concentration in parentheses, the minimum concentration must be the amount shown in the parentheses). However, in the case of preparations mainly containing the active ingredients from Group 1 of Column I or Group 2 of Column II, the minimum concentration of each active ingredient must be at

least half of the maximum concentration, and in the case of preparations mainly containing the active ingredients from Group 2 of Column I or Group 1 of Column II, the concentration is fixed to the maximum concentration.

- c) The minimum concentration of each of the active ingredients listed in Column IV, VII, or IX, Group 1 of Column X, or Groups 1 and 3 of Column XII of the Table is 1/10th of the maximum concentration (for ingredients with a concentration in parentheses, the minimum concentration must be the amount shown in the parentheses).

(3) Dosage Form

The dosage forms are liquids for external use, sprays, ointments, creams, and gels. However, for sprays, preparations mainly containing the active ingredients listed in Column I of the Table are excluded.

(4) Dosage and Administration

The preparation should be applied to the skin surface several times a day. The method of application must be clearly indicated.

(5) Indications

The indications are shown by main ingredient in the following table.

| Main ingredients | Indications |
|---------------------|--|
| Group 1 of Column I | Eczema, dermatitis, miliaria, irritated skin, itching, chilblain, insect bites, urticaria |
| Group 2 of Column I | Eczema, dermatitis, miliaria, irritated skin, itching, insect bites, urticaria |
| Column II | Eczema, dermatitis, skin sore, miliaria, irritated skin, itching, chilblain, insect bites, urticaria |

Table

| Classification | | Active ingredient | Maximum concentration (%) |
|----------------|--------------|---------------------------------|------------------------------------|
| Column I | Group 1 | Cortisone acetate | 0.5 |
| | | Dexamethasone acetate | 0.025 |
| | | Dexamethasone | 0.025 |
| | | Hydrocortisone acetate | 0.5 |
| | | Hydrocortisone | 0.5 |
| | | Prednisolone acetate | 0.25 |
| | Prednisolone | 0.25 | |
| | | Group 2 | Hydrocortisone butyrate |
| | | Prednisolone valerate acetate | 0.15 |
| Column II | Group 1 | Isotipendyl hydrochloride | 0.75 |
| | | Chlorpheniramine | 0.5 |
| | | Chlorpheniramine maleate | 1 |
| | | Diphenhydramine | 1 |
| | | Group 2 | Diphenhydramine hydrochloride |
| Column III | | Crotamiton | 10 |
| Column IV | | Glycyrrhizic acid and its salts | 1 |
| | | Glycyrrhetic acid | 1 |
| Column V | | Glycol salicylate | 2 |
| | | Methyl salicylate | 5 |
| Column VI | | Allantoin | 1 |
| Column VII | | Isopropyl methylphenol | 0.5 |
| | | Benzalkonium chloride | 0.3 |
| | | Benzethonium chloride | 0.1 |
| Column VIII | | Calamine | 8 |
| | | Zinc oxide | 37 (1.5) |
| Column IX | | Ethyl aminobenzoate | 5 |
| | | Oxy polyethoxy dodecane | 3 |
| | | Dibucaine | 0.5 |
| | | Dibucaine hydrochloride | 0.5 |
| | | Lidocaine | 2 |
| | | Lidocaine hydrochloride | 2 |
| Column X | Group 1 | <i>d</i> -Camphor | 7 (0.1) |
| | | <i>d</i> ⁺ Camphor | 7 (0.1) |
| | Group 2 | Mentha oil | 2 |
| | | <i>d</i> ⁺ Menthol | 5 (0.1) |
| | | <i>l</i> Menthol | 5 (0.1) |
| | Group 3 | <i>d</i> -Borneol | 0.3 |
| Column XI | | Ammonia water | 15 |
| Column XII | Group 1 | Tocopherol | 2 (0.1) |
| | | Tocopherol acetate | 2 (0.1) |
| | Group 2 | Panthenol | 5 |
| | Group 3 | Vitamin A oil | 500,000 I.U./100 g as vitamin A |
| | | Retinol palmitate | 500,000 I.U./100 g as vitamin A |